Silence Therapeutics plc, a biotech firm specializing in the discovery and development of innovative RNA therapeutics in areas such as hematology, cardiovascular disease, and rare metabolic conditions, is making waves in the industry. The company's cutting-edge mRNAi GOLD GalNAc Oligonucleotide Discovery platform enables them to target specific disease-related genes in the liver, while their siRNA molecules leverage the body's natural RNA interference mechanism to degrade messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. With several drugs in various phases of clinical development, including SLN360 for the reduction of high lipoprotein levels, SLN124 for the treatment of non-transfusion dependent thalassemia and myelodysplastic syndrome, and polycythemia vera, the company also boasts collaboration agreements with industry giants such as AstraZeneca PLC, Hansoh Pharmaceutical Group Company Limited, and Mallinckrodt Pharma IP Trading DAC. Founded in 1994 and based in London, the United Kingdom, Silence Therapeutics plc was previously known as SR Pharma plc and rebranded in May 2007. As the biotech industry continues to grow and evolve, Silence Therapeutics plc is poised to make a significant impact with its groundbreaking RNA therapies.
Silence Therapeutics plc's ticker is SLN
The company's shares trade on the LSE stock exchange
They are based in London, England
There are 51-200 employees working at Silence Therapeutics plc
It is http://www.silence-therapeutics.com
Silence Therapeutics plc is in the Healthcare sector
Silence Therapeutics plc is in the Biotechnology industry
The following five companies are Silence Therapeutics plc's industry peers: